iTeos Therapeutics
(NASDAQ) ITOS
iTeos Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$202.41M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
ITOS News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout iTeos Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
173
CEO
Michel Detheux, PhD
Website
www.iteostherapeutics.comHeadquarters
Watertown, MA 02472-5710, US
ITOS Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-29%
Return on Capital
-31%
Return on Assets
-25%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$33.76M
Operating Income
$159.53M
EBITDA
$121.82M
Operating Cash Flow
$98.18M
Capital Expenditure
$1.63M
Free Cash Flow
$99.81M
Cash & ST Invst.
$494.65M
Total Debt
$5.10M
iTeos Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
$0.00
-100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
173
N/A
Net Income
$78.73M
-1004.5%
EBITDA
$66.18M
-432.0%
Quarterly Fundamentals
Net Cash
$510.30M
-9.8%
Accounts Receivable
$2.55M
-94.0%
Inventory
$0.00
N/A
Long Term Debt
$3.61M
-14.8%
Short Term Debt
$1.52M
-40.6%
Return on Assets
-25.21%
N/A
Return on Invested Capital
-31.32%
N/A
Free Cash Flow
$42.73M
-24.3%
Operating Cash Flow
$42.45M
-25.1%